Tumor Cytokine-Induced Hepatic Gluconeogenesis Contributes to Cancer Cachexia: Insights from Full Body Single Nuclei Sequencing

Summary A primary cause of death in cancer patients is cachexia, a wasting syndrome attributed to tumor-induced metabolic dysregulation. Despite the major impact of cachexia on the treatment, quality of life, and survival of cancer patients, relatively little is known about the underlying pathogenic mechanisms. Hyperglycemia detected in glucose tolerance test is one of the earliest metabolic abnormalities observed in cancer patients; however, the pathogenesis by which tumors influence blood sugar levels remains poorly understood. Here, utilizing a Drosophila model, we demonstrate that the tumor secreted interleukin-like cytokine Upd3 induces fat body expression of Pepck1 and Pdk, two key regulatory enzymes of gluconeogenesis, contributing to hyperglycemia. Our data further indicate a conserved regulation of these genes by IL-6/JAK STAT signaling in mouse models. Importantly, in both fly and mouse cancer cachexia models, elevated gluconeogenesis gene levels are associated with poor prognosis. Altogether, our study uncovers a conserved role of Upd3/IL-6/JAK-STAT signaling in inducing tumor-associated hyperglycemia, which provides insights into the pathogenesis of IL-6 signaling in cancer cachexia. Graphical Abstract

[1]  U. Rix,et al.  IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells , 2022, Science Signaling.

[2]  N. Perrimon,et al.  Cancer cachexia: lessons from Drosophila , 2022, Disease models & mechanisms.

[3]  Verena C. Wimmer,et al.  Tumor-derived MMPs regulate cachexia in a Drosophila cancer model. , 2021, Developmental cell.

[4]  N. Perrimon,et al.  Coordination of tumor growth and host wasting by tumor-derived Upd3 , 2021, Cell reports.

[5]  N. Perrimon,et al.  FlyPhoneDB: An integrated web-based resource for cell-cell communication prediction in Drosophila , 2021, bioRxiv.

[6]  N. Perrimon,et al.  What fuels the fly: Energy metabolism in Drosophila and its application to the study of obesity and diabetes , 2021, Science Advances.

[7]  Alexander S. Banks,et al.  Tumor-Derived Ligands Trigger Tumor Growth and Host Wasting via Differential MEK Activation. , 2019, Developmental cell.

[8]  G. Shulman,et al.  Mechanisms of Insulin Action and Insulin Resistance. , 2018, Physiological reviews.

[9]  J. Tuszynski,et al.  Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia , 2015, Theoretical Biology and Medical Modelling.

[10]  K. Petersen,et al.  Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes , 2015, Cell.

[11]  Takashi Nishimura,et al.  Flies without Trehalose* , 2014, The Journal of Biological Chemistry.

[12]  R. Baxter,et al.  IGF binding proteins in cancer: mechanistic and clinical insights , 2014, Nature Reviews Cancer.

[13]  Robert A. Harris,et al.  Pyruvate dehydrogenase kinase-4 contributes to the recirculation of gluconeogenic precursors during postexercise glycogen recovery. , 2014, American journal of physiology. Regulatory, integrative and comparative physiology.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[16]  K. Esser,et al.  Anabolic and catabolic pathways regulating skeletal muscle mass , 2010, Current opinion in clinical nutrition and metabolic care.

[17]  M. Belury,et al.  Evidence for the contribution of insulin resistance to the development of cachexia in tumor‐bearing mice , 2010, International journal of cancer.

[18]  K. Irvine,et al.  In vivo analysis of Yorkie phosphorylation sites , 2009, Oncogene.

[19]  Claudio Cobelli,et al.  Contribution of Hepatic and Extrahepatic Insulin Resistance to the Pathogenesis of Impaired Fasting Glucose , 2007, Diabetes.

[20]  S. Khan,et al.  Regulation of glycolysis—role of insulin , 2005, Experimental Gerontology.

[21]  Robert Tjian,et al.  Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. , 2005, Genes & development.

[22]  Y. Kido,et al.  Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo , 2004, Nature Medicine.

[23]  R. Younes,et al.  Pathophysiology of cancer cachexia. , 2000, Revista do Hospital das Clinicas.

[24]  P. Heinrich,et al.  Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes , 1989, FEBS letters.

[25]  D. Blackman The economics of gluconeogenesis , 1982 .

[26]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[27]  R. Rognstad Rate-limiting steps in metabolic pathways. , 1979, The Journal of biological chemistry.

[28]  T. Scherstén,et al.  Insulin resistance in patients with cancer. , 1978, Cancer research.

[29]  T. Stein Cachexia, gluconeogenesis and progressive weight loss in cancer patients. , 1978, Journal of theoretical biology.

[30]  C. Waterhouse Lactate metabolism in patients with cancer , 1974, Cancer.

[31]  G. L. Rohdenburg,et al.  SUGAR TOLERANCE IN CANCER , 1919 .

[32]  T. H. Holmes,et al.  Mechanisms of Skeletal Muscle , 2015 .

[33]  W. Liang,et al.  TM4 microarray software suite. , 2006, Methods in enzymology.

[34]  S. Eckert,et al.  [Glucose metabolism]. , 2005, Zeitschrift fur Kardiologie.

[35]  B. Barton IL-6-like cytokines and cancer cachexia , 2001, Immunologic research.

[36]  P. Fournier,et al.  Regulation of pyruvate , 1998 .

[37]  N. Kraus-Friedmann Hormonal regulation of hepatic gluconeogenesis. , 1984, Physiological reviews.